Our site uses cookies to offer you a better user experience. By continuing to use this site, you agree to our use of cookies. To find out more, read our Privacy and Cookies policies.
  • All Journals
  • Exploration of Medicine
  • Exploration of Targeted Anti-tumor Therapy
  • Exploration of Immunology
  • Exploration of Neuroprotective Therapy
  • Exploration of Digestive Diseases
  • Exploration of Neuroscience
  • Exploration of Musculoskeletal Diseases
  • Exploration of Drug Science
  • Exploration of Asthma & Allergy
  • Exploration of Foods and Foodomics
  • Exploration of Digital Health Technologies
  • Exploration of Cardiology
  • Exploration of BioMat-X
  • Exploration of Endocrine and Metabolic Diseases
  • All
  • Article Title
  • Abstract
  • Keywords
  • Author
  • Institution
1608 results for in Open Exploration
  • Relevance
  • Publication Date
Sort by :
Open Access Review
The impact of tumour pH on cancer progression: strategies for clinical intervention
Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi  [...] Read more.
Carol Ward, James Meehan, Mark E Gray, Alan F Murray, David J Argyle, Ian H Kunkler, Simon P Langdon
Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
21543 767 99
Open Access Case Report
Multiple adverse drug reactions during all-trans retinoic acid treatment for acute promyelocytic leukemia: differentiation syndrome, bradycardia, intestinal necrosis
All-trans retinoic acid (ATRA) induces complete remission in a high proportion of acute promyelocytic leukemia (APL). Nevertheless it is be associated with adverse drug reactions that might be life-  [...] Read more.
Valeria Ferla, Mariarita Sciumé, Umberto Gianelli, Luca Baldini, Nicola Stefano Fracchiolla
Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:109–116
3242 24 3
Open Access Review
Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
Several preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advance  [...] Read more.
Giuliano Palumbo, Giovanna Esposito, Guido Carillio, Anna Manzo, Agnese Montanino, Vincenzo Sforza, Raffaele Costanzo, Claudia Sandomenico, Carmine La Manna, Nicola Martucci, Antonello La Rocca, Giuseppe De Luca, Maria Carmela Piccirillo, Rossella De Ceci
Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:117–130
3545 63 2
Open Access Review
Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease
Non-alcoholic fatty liver disease (NAFLD) remains a major cause of chronic liver disease worldwide. Despite extensive studies, the heterogeneity of the risk factors as well as different disease mechanisms complicate the goals towa  [...] Read more.
Noel C. Salvoza, Pablo J. Giraudi, Claudio Tiribelli, Natalia Rosso
Published: April 30, 2020 Explor Med. 2020;1:51–74
12437 252 19
Open Access Review
Understanding cardiac systolic performance beyond left ventricular ejection fraction
Left ventricular ejection fraction is the critical parameter used for heart failure classification, decision making and assessing prognosis. It is defined as a volumetric ratio and is essentially a composite of arterial and ventri  [...] Read more.
Elena-Laura Antohi, Ovidiu Chioncel
Published: April 30, 2020 Explor Med. 2020;1:75–84
8037 164 5
Open Access Review
Perspectives of nonalcoholic fatty liver disease research: a personal point of view
Rational government of patient fluxes from primary care to hepatology clinic is a priority of nonalcoholic fatty liver disease (NAFLD) research. Estimating pre-test probability of disease, risk of fibrosis progression, and exclusi  [...] Read more.
Amedeo Lonardo, Stefano Ballestri
Published: June 29, 2020 Explor Med. 2020;1:85–107
8765 130 25
Open Access Review
Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell   [...] Read more.
Rachael Arthur, Beatriz Valle-Argos, Andrew J. Steele, Graham Packham
Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
8680 297 18
Open Access Original Article
Reduction of endoglin receptor impairs mononuclear cell-migration
Aim: To test if the impairment of mononuclear cell (MNC) migration in patients with hereditary hemorrhagic telangiectasia (HHT) is due to the reduction of the endoglin (ENG) receptor on the cell surface and oxidative stress. M  [...] Read more.
Zhenying Han, Sonali Shaligram, Marie E. Faughnan, Dewi Clark, Zhengda Sun, Hua Su
Published: June 29, 2020 Explor Med. 2020;1:136–148
3337 33 8
Open Access Original Article
Placental OPRM1 DNA methylation and associations with neonatal opioid withdrawal syndrome, a pilot study
Aim: Epigenetic variation of DNA methylation of the mu-opioid receptor gene (OPRM1) has been identified in the blood and saliva of individuals with opioid use disorder (OUD) and infants with neonatal opioid withdrawal syndrome   [...] Read more.
Elisha M. Wachman, Alice Wang, Breanna C. Isley, Jeffery Boateng, Jacob A. Beierle, Aaron Hansbury, Hira Shrestha, Camron Bryant, Huiping Zhang
Published: June 29, 2020 Explor Med. 2020;1:124–135
4543 50 9
Open Access Meta-Analysis
GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis
Aim: Recent randomized controlled trials (RCTs) have tested the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) to specifically treat non-alcoholic fatty liver disease (NAFLD). We performed a meta-analysis of R  [...] Read more.
Alessandro Mantovani, Giorgia Beatrice, Graziana Petracca, Filippo Pampagnin, Damiano Sandri, Giovanni Targher
Published: June 29, 2020 Explor Med. 2020;1:108–123
4324 101 4
Open Access Review
An overview of the anti-cancer actions of Tanshinones, derived from Salvia miltiorrhiza (Danshen)
Tanshinone is a herbal medicinal compound described in Chinese medicine, extracted from the roots of Salvia miltiorrhiza (Danshen). This family of compounds, including Tanshinone IIA and Tanshinone  [...] Read more.
Irum Naz, Myriam Merarchi, Shanaya Ramchandani, Muhammad Rashid Khan, Muhammad Nouman Malik, Sumaira Sarwar, Acharan S Narula, Kwang Seok Ahn
Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:153–170
6593 104 15
Open Access Review
Nonalcoholic fatty liver disease and portal hypertension
Nonalcoholic fatty liver disease (NAFLD) is a substantial and growing problem worldwide and has become the second most common indication for liver transplantation as it may progress to cirrhosis and develop complications from port  [...] Read more.
Marvin Ryou, Nicholas Stylopoulos, Gyorgy Baffy
Published: June 29, 2020 Explor Med. 2020;1:149–169
9400 139 29
Open Access Review
Role of liquid biopsy for thoracic cancers immunotherapy
Immunotherapy has shifted the therapeutic landscape in thoracic cancers. However, assessment of biomarkers for patient selection and disease monitoring remain challenging, especially considering the  [...] Read more.
Raimondo Di Liello, Flora Cimmino, Soraya Simón, Emilio Francesco Giunta, Vincenzo De Falco, Paloma Martín-Martorell
Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:183–199
4386 60 6
Open Access Review
Integration of PARP-inhibitors in ovarian cancer therapy
Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting.  [...] Read more.
Antonella Pietragalla, Francesca Ciccarone, Camilla Nero, Giovanni Scambia, Domenica Lorusso, Gennaro Daniele
Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:171–182
3181 40 4
Open Access Review
The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis
Pooled prevalence of nonalcoholic fatty liver disease (NAFLD) globally is about 25%. Nonalcoholic steatohepatitis (NASH) with advanced fibrosis has been linked with substantial morbidity and mortality, without having to-date any l  [...] Read more.
Michael Doulberis, Kasiani Papadimitriou, Apostolis Papaefthymiou, Jannis Kountouras, Stergios A. Polyzos
Published: August 31, 2020 Explor Med. 2020;1:170–183
5288 72 5
Open Access Perspective
Visual communication and learning from COVID-19 to advance preparedness for pandemics
The currently ongoing coronavirus disease 19 (COVID-19) pandemic has affected globally human health and economy. Research in progress has shown facts associated with this disease and raised questions relevant for disease control a  [...] Read more.
José de la Fuente, José Bedia, Christian Gortázar
Published: August 31, 2020 Explor Med. 2020;1:244–247
4812 70 2
Open Access Review
A brief overview of antitumoral actions of bruceine D
Cancer remains the second leading cause of mortality globally. In combating cancer, conventional chemotherapy and/or radiotherapy are administered as first-line therapy. However, these are usually a  [...] Read more.
Zi Wayne Sin, Vipul Bhardwaj, Amit Kumar Pandey, Manoj Garg
Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:200–217
4462 67 9
Open Access Review
Type 2 diabetes and cancer: problems and suggestions for best patient management
Diabetes and cancer are widespread worldwide and the number of subjects presenting both diseases increased over the years. The management of cancer patients having diabetes represents a challenge not only because of the complexity  [...] Read more.
Agostino Milluzzo, Paolo Vigneri, Federica Martorana, Riccardo Vigneri, Laura Sciacca
Published: August 31, 2020 Explor Med. 2020;1:184–204
9437 177 13
Open Access Review
Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease
The prevalence of nonalcoholic or more recently re-defined metabolic associated fatty liver disease (MAFLD) is rapidly growing worldwide. It is characterized by hepatic fat accumulation exceeding 5% of liver weight not attributabl  [...] Read more.
Marica Meroni, Miriam Longo, Paola Dongiovanni
Published: August 31, 2020 Explor Med. 2020;1:218–243
5835 111 4
Open Access Review
Future directions and management of liquid biopsy in non-small cell lung cancer
Lung cancer represents the world’s most common cause of cancer death. In recent years, we moved from a generic therapeutic strategy to a personalized approach, based on the molecular char  [...] Read more.
Alessia Maria Cossu, Marianna Scrima, Angela Lombardi, Anna Grimaldi, Margherita Russo, Alessandro Ottaiano, Michele Caraglia, Marco Bocchetti
Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:239–252
4052 67 8